Anthony J. Gringeri, Ph.D,
President and Chief Executive Officer
Dr. Gringeri was appointed Chief Executive Officer in December 2016. He joined ImmunoCellular Therapeutics in August 2013 as Senior Vice President, Strategic Resources. Dr. Gringeri has more than 25 years of executive experience in the pharmaceutical and biotechnology industry, having successfully led multiple functions and cross-functional teams throughout his career, including in the areas of clinical, regulatory and commercial planning and operations, finance, licensing and alliance management. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer, responsible for all preclinical, clinical and regulatory activities.
Previously, Dr. Gringeri served as Chief Operating Officer for Amsterdam Molecular Therapeutics, where he was responsible for corporate strategy and operations, business development, building the company’s commercial capability, and played a key role in its initial public offering. Dr. Gringeri worked with Amgen for 15 years in a series of executive leadership roles. Dr. Gringeri was the Vice President, Product Development, responsible for the successful development and commercialization of ARANESP® (darbepoetin alfa). Dr. Gringeri holds a PhD in pharmacology from the University of Rochester and has authored multiple scientific publications.
John S. Yu, M.D.,
Dr. Yu is a founder and scientific impetus behind ImmunoCellular Therapeutics. The technology was licensed from his NIH-funded laboratory where he conducts extensive research in immunotherapies. As a physician-scientist, his area of expertise is in immunotherapies and in cancer stem cell biology.
He was inducted into Castle and Connelly's America's Top Doctors in 2005. Dr. Yu has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science and Journal of Neurosurgery.
Dr. Yu earned his bachelor's degree in French literature and biological sciences from Stanford University and spent a year at the Sorbonne in Paris studying French literature while pursuing a fellowship in immunology at the Institut Pasteur in Paris. He earned his medical degree from Harvard Medical School and master's degree from the Harvard University's Department of Genetics. He completed his neurosurgical residency at Massachusetts General Hospital (MGH) in Boston. In addition, he was a Neuroscience Fellow at the National Institutes of Mental Health in the Neuroimmunology Unit at MGH from 1988 to 1989 and was a Culpepper Scholar in the hospital’s Molecular Neurogenetics Unit from 1993 to 1995.
Dr. Yu's other honors include the Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995. He received the Academy Award from the American Academy of Neurological Surgery at its 1996 annual meeting. Other honors include the Young Investigator Award from the Congress of Neurological Surgeons in 2000, the National Brain Tumor Foundation Grant in 2001, and the Mahaley Clinical Research award from the American Association of Neurological Surgeons in 2005. Dr. Yu is a member of the full-time faculty in the Department of Neurosurgery at Cedars-Sinai Medical Center. An internationally renowned neurosurgeon, Dr. Yu's clinical focus is on the treatment of malignant and benign brain and spinal tumors.
Steven J. Swanson, Ph.D.,
Senior Vice President, Research
Prior to joining ImmunoCellular, Dr. Swanson was an independent consultant advising biopharmaceutical companies on basic immunology research, bioanalytical procedures, immunogenicity assessment, regulatory affairs and product quality. Dr. Swanson spent 15 years at Amgen as Department Head for Clinical Immunology, a then-new department providing immunogenicity and cytometry support for all of Amgen’s therapeutic proteins. Prior to joining Amgen, he led the immunoassay laboratory in the Biotechnology department at Schering Plough Research Institute. Dr. Swanson has been actively involved in multiple industry professional associations, including the American Association of Pharmaceutical Scientists (AAPS), where he is a Fellow, and was a co-author of AAPS-sponsored Industry White Papers that were incorporated into FDA and EMA Guidance for Immunogenicity Assessment. He was also an industry representative for the EMA Committee that developed the first Immunogenicity Recommendations, and was engaged by the FDA to train reviewers on immunogenicity assessment. Dr. Swanson has authored more than 60 publications. He holds a BA in chemistry/biology from North Central College, a PhD in microbiology from the University of Iowa, and completed a post-doctoral fellowship at The Ohio State University.
Vice President, Finance and Principal Accounting Officer
Mr. Fractor has served as ImmunoCellular Therapeutics’ Treasurer and Vice President, Finance on a part-time basis since April 2011. Since 2003, Mr. Fractor has been a consultant providing financial consulting and strategic planning services, including Sarbanes-Oxley compliance consulting services, to a variety of companies in a variety of industries. From 1999 through 2003, Mr. Fractor was the Chief Financial Officer of HemaCare Corporation. Previously, Mr. Fractor was in public practice of accounting, having served as an audit manager at Deloitte and also at a regional accounting firm. Mr. Fractor received his B.S. in Accounting from the University of Southern California in 1982, is a certified public accountant and a member of AICPA and the California Society of CPAs.
Vice President, Cell Therapy Manufacturing
Ms. Schilling joined ImmunoCellular Therapeutics as a consultant for manufacturing in January 2014 and later as Vice President, Cell Therapy Manufacturing in 2015.
Ms. Schilling has over 25 years of experience specializing in autologous and allogeneic cellular therapy ranging from R&D, device development and optimization, automation, contract manufacturing organizations (CMOs), GMP/GLP/GTP, technical support, scale up and translational process development. Prior to joining ImmunoCellular Therapeutics, she was VP of Manufacturing for Prima BioMed overseeing CMC activities for a global Phase II autologous DC program. Previous roles included Technical Director and Sr. Director of Operations and Process Development at Progenitor Cell Therapy, Mountain View and as Associate Director of Cell Processing at Immunodesigned Molecules. Marta started her career at Baxter (later Nexell Therapeutics) holding various roles over 17 years focused on the development and support of the Isolex®, a CD34+ stem cell selection device along with various cell therapy products and applications. Marta holds a B.S. in Medical Technology with a specialty in Hematology from the University of Vermont.